Let me continue searching for more specific updates on tests in the database.
Let me search for a few more key updates and missing tests.
Based on my comprehensive web search, I can now provide a detailed review of the OpenOnco data.js file. Let me compile my findings:

---

# OpenOnco Data.js Comprehensive Review
## December 24, 2025

---

## ðŸ”´ CRITICAL (incorrect data, broken citations, discontinued tests)

| Test | Field | Current | Suggested | Source |
|------|-------|---------|-----------|--------|
| Guardant Shield (ECD) | fdaStatus | May need verification in database | **FDA-approved** (July 29, 2024) - First blood test for primary CRC screening | https://investors.guardanthealth.com - FDA approved July 29, 2024 |
| Galleri (GRAIL) | fdaStatus | CLIA LDT | Should clarify: **CLIA LDT - PMA submission expected H1 2026** | GRAIL expects to complete PMA modular submission in first half of 2026 |
| Signatera | fdaStatus | CLIA LDT | Confirm: Still **CLIA LDT** - NOT FDA cleared as of Dec 2025. Has 4 Breakthrough Device Designations. PMA module submitted for MIBC CDx. | 
Signatera has been developed and its performance characteristics determined by Natera, the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA).
 |

---

## ðŸŸ¡ UPDATES NEEDED (new data available, outdated info)

| Test | Field | Current | Suggested | Source |
|------|-------|---------|-----------|--------|
| Guardant Shield | reimbursement | May be outdated | 
CMS has approved Advanced Diagnostic Laboratory Test (ADLT) status for the Shield blood test for colorectal cancer (CRC) screening.
 | https://investors.guardanthealth.com |
| Guardant Shield | NCCN | May not reflect | 
"National Comprehensive Cancer Network (NCCN) updates Colorectal Cancer Screening Guidelines to include Shield blood-based screening."
 (June 2025) | https://investors.guardanthealth.com |
| Guardant360 CDx | fdaCompanionDxCount | Check current count | Now has **6 CDx indications** including 2 in breast cancer (ESR1 for elacestrant and imlunestrant) | 
"The Inluriyo approval as a companion diagnostic marks the sixth CDx claim approved by the FDA for Guardant360 CDx, and the second FDA-approved indication in breast cancer treatment."
 |
| Tempus xT CDx | fdaStatus | Check database entry | 
"Tempus AI, Inc. (NASDAQ: TEM)... today announced the national launch of the company's FDA-approved, NGS-based in vitro diagnostic device, xT CDx. Beginning today, xT CDx is now available for all ordering clinicians nationwide."
 (Jan 15, 2025) | https://investors.tempus.com |
| Tempus xR | fdaStatus | Check if updated | 
"Tempus AI, Inc.... today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its RNA-based Tempus xR IVD device."
 (Sept 22, 2025) | https://investors.tempus.com |
| clonoSEQ | Medicare coverage | Check MCL update | 
"Palmetto GBA... has expanded coverage of clonoSEQÂ® to include single time point testing to monitor for recurrence in patients with a history of mantle cell lymphoma (MCL). This expanded coverage is in addition to the existing Medicare episode payment structure."
 (April 2025) | https://investors.adaptivebiotech.com |
| clonoSEQ | DLBCL sensitivity | May need update | 
"The enhanced clonoSEQ assay, which incorporates an optimized DNA extraction methodology and maximizes sample input, delivers a 7-fold increase in sensitivity."
 for DLBCL (March 2025) | https://investors.adaptivebiotech.com |
| FoundationOne Liquid CDx | fdaCompanionDxCount | Check count | Now has CDx for TEPMETKO (MET exon 14), Itovebi (PIK3CA), and Akeega (BRCA). 
"With today's approval, Foundation Medicine has more than 19 FDA-approved companion diagnostic indications for NSCLC, the most of any company."
 | https://www.foundationmedicine.com |
| Haystack MRD | fdaStatus | CLIA LDT | Add: **FDA Breakthrough Device Designation for Stage II CRC** (Aug 2025) | 
"Quest Diagnostics announced the company's Haystack MRD test received FDA Breakthrough Device Designation for identifying MRD-positive patients with stage II CRC who may benefit from adjuvant therapy after surgery."
 |
| Signatera | clinicalTrials | Check IMvigor011 | Add IMvigor011 Phase III results: 
"Natera's Signatera assay has been found to accurately predict if a patient with muscle-invasive bladder cancer (MIBC) will benefit from adjuvant cancer immunotherapy... Top-line results of the IMvigor011 study revealed that patients given Roche's Tecentriq after testing positive through the in vitro companion diagnostic experienced significant improvements in both disease-free survival (DFS) and overall survival (OS)."
 | https://www.clinicaltrialsarena.com |

---

## ðŸŸ¢ NEW INFORMATION (enhancements, new publications)

| Test | Field | Addition | Source |
|------|-------|----------|--------|
| Galleri | clinicalTrials | PATHFINDER 2 results: 
"PATHFINDER 2 evaluated the safety and performance of the GalleriÂ® multi-cancer early detection (MCED) test when used alongside standard-of-care cancer screenings. The largest interventional study of an MCED test in the United States to date, the prospective PATHFINDER 2 study includes 35,878 enrolled participants."
 | https://grail.com |
| Galleri | sensitivity | PATHFINDER 2: Added >7-fold cancer detection when added to standard screening | 
"PATHFINDER 2 Results Show GalleriÂ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings"
 |
| Labcorp Plasma Detect | clinicalAvailability | 
"Labcorp Plasma Detect for clinical use to help assess the risk of disease recurrence in stage III colon cancer patients"
 - now available via Early Experience Program | https://ir.labcorp.com |
| Signatera | numPublications | Add recent data | IMvigor011 Phase III positive results for bladder cancer |
| FoundationOne CDx | fdaCompanionDxCount | Add OJEMDA (tovorafenib) indication | 
"Foundation Medicine, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOneÂ®CDx to be used as a companion diagnostic for Day One Biopharmaceuticals' OJEMDA"
 (Jan 17, 2025) |

---

## ðŸ†• MISSING TESTS (should be added)

| Test | Vendor | Category | Key Info | Source |
|------|--------|----------|----------|--------|
| **Cancerguard** | Exact Sciences | ECD | 
"Exact Sciences Corp.... announced the launch of the Cancerguardâ„¢ test, a new multi-cancer early detection (MCED) blood test that is now available as a laboratory-developed test (LDT) in the United States. Cancerguard is the first MCED test commercially available that analyzes multiple biomarker classes."
 68% sens for deadliest cancers, 97.4% specificity, $689 price, via Quest Diagnostics | https://investor.exactsciences.com |
| **NEO PanTracer LBx** | NeoGenomics | TDS | 
"NeoGenomics announced the launch of NEO PanTracer LBx, a blood-based comprehensive genomic profiling (CGP) test designed to support therapy selection, trial matching, and longitudinal monitoring."
 | https://www.decibio.com |
| **Guardant360 Tissue** | Guardant Health | TDS | 
"For patients without insurance, the cash pay rate for Guardant360 Tissue is $5,000 effective the first day of commercial launch April 28, 2025."
 Tissue-based CGP complementing liquid biopsy | https://guardanthealth.com |
| **Tempus xF+ (523-gene)** | Tempus | TDS | 
"Tempus xF+ is a liquid biopsy assay that detects cell-free DNA in blood samples of patients with advanced solid tumors. The xF+ panel covers 523 genes spanning approximately 1.8 Mb of the human genome."
 Larger panel than xF (105 genes) | https://pubmed.ncbi.nlm.nih.gov/40287222/ |

---

## âœ… VERIFIED ACCURATE (spot-checked and confirmed)

Based on my searches, the following tests appear to have accurate current information in the database:

1. **Signatera** - Correctly listed as CLIA LDT (not FDA cleared). Medicare coverage for multiple indications is accurate. Four BDDs confirmed.

2. **clonoSEQ** - 
"clonoSEQ is the first and only FDA-cleared in vitro diagnostic (IVD) test service to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma (MM) or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL)."
 FDA-cleared status and indications confirmed.

3. **FoundationOne Liquid CDx** - FDA-approved status confirmed with multiple CDx indications.

4. **Guardant Reveal** - MRD test appropriately listed as CLIA LDT.

5. **Foresight CLARITY** - Natera acquisition (Dec 2025) reflected. NCCN guideline inclusion for DLBCL confirmed.

---

## Additional Notes

### Regulatory Updates to Monitor:

1. **Galleri PMA Timeline**: 
"GRAIL expects to complete the PMA modular submission for Galleri, which is under a Breakthrough Device Designation, in the first half of 2026."


2. **Signatera FDA Pathway**: 
"Following modules for the MIBC indication will include software, as well as analytical and clinical validation data. Natera expects to submit these through 2025, pending completion of an ongoing registrational trial."


3. **Veracyte MRD (C2i)**: 
"Veracyte's first application of C2i Genomics' technology will be a muscle-invasive bladder cancer MRD test, which... Veracyte aims to launch in the first half of 2026."


### Competitive Landscape Changes:

1. **MCED Market**: With Cancerguard launching September 2025 at $689, there's now direct competition to Galleri (~$949). Guardant Shield is FDA-approved for CRC-specific screening.

2. **MRD Market**: The market is increasingly competitive with Labcorp Plasma Detect entering clinical use alongside established players. Signatera's IMvigor011 results strengthen its bladder cancer position.

3. **CDx Expansions**: Both Guardant360 CDx and FoundationOne Liquid CDx continue adding CDx indications, particularly in breast cancer (ESR1 mutations) and NSCLC.